4 results
Approved WMOCompleted
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma
Approved WMOCompleted
The purpose of this study is to look at the effect of changing from monthly (4 weekly) injections of your usual treatment (octreotide LAR) to less frequent treatment (once every 6 or 8 weeks) with lanreotide Autogel 120 mg injections. The study…
Approved WMOCompleted
see protocol summary
Approved WMOCompleted
The primary hypothesis of this study is that a dose-response relationship exists between disease activity as measured by the change from baseline in the Mayo score at Week 8 and JNJ-54781532 treatment regimens in subjects with moderately to severely…